Dopamine depleters in the treatment of hyperkinetic movement disorders.
about
How Much Do We Know about Adult-onset Primary Tics? Prevalence, Epidemiology, and Clinical FeaturesDifferences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and ValbenazineAntipsychotic-induced Tardive dyskinesia: from biological basis to clinical management.Hemichorea caused by nonketotic hyperosmolar state: A case report and review of the literature.Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?Toward a Multifactorial Conception of the Gilles de la Tourette Syndrome and Persistent Chronic Tic Disorder.Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea.The efficacy and safety of riluzole for neurodegenerative movement disorders: a systematic review with meta-analysis.Movement disorders and chronic psychosis: Five new things.Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.Characterizing a mouse model for evaluation of countermeasures against hydrogen sulfide-induced neurotoxicity and neurological sequelae.Treatment options for chorea.Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less "go" and more "stop" from the motor striatum for robust therapeutic effects.Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.Successful treatment of choreo-athetotic movements in a patient with an EEF1A2 gene variantAltered dopamine release and monoamine transporters in Vps35 p.D620N knock-in mice
P2860
Q30234351-17EAD1F5-B5E1-4D7E-9E26-B004CC4B1D69Q38641750-49E9236D-4BE4-49CF-BDED-CA08FDD2CEC3Q38657158-517BFD35-A27F-4F99-B7E1-8473920F1609Q39006070-8A7D24C0-DD0D-4790-9C99-4496862D79AAQ41540646-9DF411F8-5B6C-4A3A-AF0E-32155C0F99DAQ42334772-E12646E4-CFEE-4BEF-A89E-C769D277B8FDQ45062996-2E037E26-20DB-4BD3-A2D0-0938D4AAC5CAQ47332706-76DC0807-93D4-476D-B40B-8A62BD47B2C9Q47398683-48049FE0-1D4B-4016-ACBC-3FBC3958B946Q47753620-B7F7BC7D-5681-4B37-A443-85BDE8A4AF85Q47822882-79B5838F-D96A-4DFD-BD03-9E53BEEE0FEBQ47977953-4E564AE0-6005-4A6B-B53C-9064C3418330Q49716344-49D79F58-5778-4154-BECF-FC5DD177EC18Q54969812-9772B76E-078A-464F-A0B3-90F96F52C43EQ58119044-FD7AFD49-C26D-43E4-A1FB-4EED4D60F3AFQ58730704-C53C9E59-7787-4A36-9D39-DF92909628D6
P2860
Dopamine depleters in the treatment of hyperkinetic movement disorders.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Dopamine depleters in the treatment of hyperkinetic movement disorders.
@en
Dopamine depleters in the treatment of hyperkinetic movement disorders.
@nl
type
label
Dopamine depleters in the treatment of hyperkinetic movement disorders.
@en
Dopamine depleters in the treatment of hyperkinetic movement disorders.
@nl
prefLabel
Dopamine depleters in the treatment of hyperkinetic movement disorders.
@en
Dopamine depleters in the treatment of hyperkinetic movement disorders.
@nl
P2860
P1476
Dopamine depleters in the treatment of hyperkinetic movement disorders.
@en
P2860
P304
P356
10.1080/14656566.2016.1258063
P407
P577
2016-11-06T00:00:00Z